November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Maxime Dely – The French Transfusion landscape is Evolving
Nov 13, 2025, 01:14

Maxime Dely – The French Transfusion landscape is Evolving

Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:

”The French transfusion landscape is evolving

As hospital needs change and health sovereignty becomes a national priority, the 2024 Annual Report of the French Blood Establishment (EFS) highlights a major transformation in the countryโ€™s transfusion system.

Red blood cell use continues to decline

The number of red blood cell (RBC) units issued keeps decreasing:

  • 2,081,938 units delivered in 2024
  • -3.4 % compared to 2023

This trend reflects:

โ€ข More efficient use of transfusion indications
โ€ข Improved patient blood management
โ€ข Optimization of clinical practices

Plasma takes center stage

Conversely, plasma collection is growing rapidly:

  • 867,127 liters of plasma for fractionation delivered in 2024 (+4.8%)
  • +1.4 % plasma donors in one year

This growth supports the national strategy โ€œAmbition Plasmaโ€, with an ambitious goal:

1.4 million liters of plasma collected per year by 2028

To reach this target, EFS is:

โ€ข Progressively shifting from whole blood to plasma donations,
โ€ข Opening new donation centers and time slots,
โ€ข Expanding remote medical supervision (tele-assistance) to facilitate apheresis donations.

A strong and encouraging donor engagement

In 2024:

  • 1,506,534 donors – including 17 % new donors
  • 29 % under 30 years old – a promising new generation of donors
  • A strong sense of commitment that secures the future of blood and plasma supply

The generational renewal is a key success factor for sustaining the transfusion system in the years to come.

A structural shift

2024 confirms a deep transformation:

  • Fewer red blood cell transfusions
  • More plasma collected, better utilized, and more strategic than ever

A crucial evolution to meet therapeutic needs, strengthen the national supply of plasma-derived medicines, and support France’s health sovereignty.

What’s next?

How can we accelerate this transition while maintaining donor loyalty and the right balance between all blood components?

Iโ€™d love to hear your insights, experiences, and perspectives.”

Transfusion

 

Stay updated with Hemostasis Today.